AR112188A1 - ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS - Google Patents

ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS

Info

Publication number
AR112188A1
AR112188A1 ARP180101347A AR112188A1 AR 112188 A1 AR112188 A1 AR 112188A1 AR P180101347 A ARP180101347 A AR P180101347A AR 112188 A1 AR112188 A1 AR 112188A1
Authority
AR
Argentina
Prior art keywords
papain
oral composition
pectin
prepare
methods
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Mauricio Dobboletta
Original Assignee
Brix S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brix S R L filed Critical Brix S R L
Priority to ARP180101347 priority Critical patent/AR112188A1/en
Priority to PCT/US2019/031326 priority patent/WO2019226349A1/en
Publication of AR112188A1 publication Critical patent/AR112188A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición oral a base de pectina y papaína para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan, dicha composición comprende pectina de por lo menos 65% de ácido D-galacturónico y papaína con una actividad proteolítica de por lo menos 6.000 U/mg, en donde la pectina y la papaína tienen una relación en peso efectiva de aproximadamente 250:3, respectivamente, y se encuentran humectadas por medio de al menos dos polioles de C₃₋₆, siendo el pH de la composición del orden de 6 obtenido con el agregado de al menos una alcanolamida de C₂₋₆, y comprendiendo además emulsionantes, conservantes y solventes farmacéuticamente aceptables. Métodos para preparar dicha composición oral en cápsula blanda y en jarabe. Método para disminuir los niveles de IGF-1 libre en plasma de personas que lo necesitan con dicha composición oral; que comprende administrara dichas personas una dosificación comprendiendo al menos aproximadamente 250 mg de pectina y al menos aproximadamente 3 mg de papaína cada por lo menos 12 horas durante al menos 28 días. Uso de pectina y papaína en forma conjunta para preparar dicha composición oral.Oral composition based on pectin and papain to decrease the levels of free IGF-1 in plasma of people who need it, said composition comprises pectin of at least 65% of D-galacturonic acid and papain with a proteolytic activity of at least 6,000 U / mg, where pectin and papain have an effective weight ratio of approximately 250: 3, respectively, and are moistened by means of at least two C pol polyols, the pH of the composition being of the order of 6 obtained with the addition of at least one C₂₋₆ alkanolamide, and also comprising emulsifiers, preservatives and pharmaceutically acceptable solvents. Methods for preparing said soft capsule and syrup oral composition. Method to decrease the levels of free IGF-1 in plasma of people who need it with said oral composition; which comprises administering said persons a dosage comprising at least about 250 mg of pectin and at least about 3 mg of papain every at least 12 hours for at least 28 days. Use of pectin and papain together to prepare said oral composition.

ARP180101347 2018-05-22 2018-05-22 ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS AR112188A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP180101347 AR112188A1 (en) 2018-05-22 2018-05-22 ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS
PCT/US2019/031326 WO2019226349A1 (en) 2018-05-22 2019-05-08 Oral composition of citrus pectin and papain to decrease plasma free igf-1 levels in individuals who need it and methods of preparation in soft capsule and syrup dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP180101347 AR112188A1 (en) 2018-05-22 2018-05-22 ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS

Publications (1)

Publication Number Publication Date
AR112188A1 true AR112188A1 (en) 2019-10-02

Family

ID=68382491

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101347 AR112188A1 (en) 2018-05-22 2018-05-22 ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS

Country Status (2)

Country Link
AR (1) AR112188A1 (en)
WO (1) WO2019226349A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115212226A (en) * 2021-04-20 2022-10-21 涛护集团有限公司 Application of pectin in preparing health product/medicine for improving/reversing chronic kidney disease caused by virus or medicine damage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916541B2 (en) * 2011-01-05 2014-12-23 Better Health Publishing, Inc. Synergistic combination of honokiol and modified citrus pectin in cancer therapy
US8333961B2 (en) * 2007-07-03 2012-12-18 Privitera James R Natural liniment for treatment of skin cancers
AR102008A1 (en) * 2015-09-24 2017-01-25 Brix S R L ACTIVE PHARMACEUTICAL INGREDIENT (IFA) OLEOUS FOR THE TREATMENT OF SKIN AFFECTIONS, COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE THEM
WO2017184851A1 (en) * 2016-04-20 2017-10-26 La Jolla Pharmaceutical Company Compositions and methods for treating cancer

Also Published As

Publication number Publication date
WO2019226349A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
CO2020009670A2 (en) Compositions comprising the co-selected microbiota and methods for their use
CO2019000945A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CO5680456A2 (en) COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS
CO2019000943A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
EA200601761A1 (en) COMPOSITIONS AS ADJUVANTS FOR STRENGTHENING IMMUNE RESPONSES TO VACCINES AND METHODS OF THEIR USE
CO2019000944A2 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof
AR105027A1 (en) METHODS OF TREATMENT OF LOCALLY ADVANCED OR METASTASIC BREAST CANCER USING ANTAGONISTS OF THE PD-1 AND TAXAN AXIS
CO2019000941A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA202191079A1 (en) METHODS FOR TREATMENT OF RETTA SYNDROME WITH FENFLURAMINE
CL2019003441A1 (en) Mic-1 posts and uses of these.
AR112166A1 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
CL2019003533A1 (en) Use of vibegron to treat overactive bladder.
AR112188A1 (en) ORAL COMPOSITION OF CITRUS PECTIN AND PAPAIN, METHODS TO PREPARE IT IN SOFT CAPSULE AND SYRUP DOSAGE FORMS
DK1091733T3 (en) (-) - Pseudoephedrine as a sympathomimetic drug
MX2022006940A (en) Pharmaceutical compositions comprising cabotegravir.
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
DOP2022000004A (en) PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD
AR046665A1 (en) ORAL FORMULATIONS OF DEOXIPEGANINE AND ITS USES
MX2022008036A (en) New use of bcg immunogenic formulation expressing a respiratory syncitial virus protein against hmpv.
AR120399A1 (en) A METHOD OF TREATMENT OF A DLL3 POSITIVE CANCER